Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products geared towards addressing unmet needs and providing unique and meaningful advantages to patients with renal disease and their healthcare providers. Patients have been and continue to be at the center of our 16-year corporate history.
Company Growth (employees)
Type
Public
HQ
New York, US
Size (employees)
193 (est)
Website
keryx.com
Keryx Biopharmaceuticals is headquartered in New York, US

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in New York and Boston
New York, US (HQ)
750 Lexington Ave., 20th Floor
Boston, US
One Marina Park Drive, 12th Floor

Keryx Biopharmaceuticals Financials and Metrics

Keryx Biopharmaceuticals Financials

Keryx Biopharmaceuticals's revenue was reported to be $32 m in FY, 2016
USD

Revenue (Q2, 2017)

15.1 m

Gross profit (Q2, 2017)

10.8 m

Gross profit margin (Q2, 2017), %

71%

Net income (Q2, 2017)

(86.5 m)

EBIT (Q2, 2017)

(23.9 m)

Market capitalization (13-Nov-2017)

583.1 m

Cash (30-Jun-2017)

140.5 m
Keryx Biopharmaceuticals's current market capitalization is $583.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7 m10.8 m13.7 m32 m

Revenue growth, %

55%26%134%

Cost of goods sold

37.8 m

Gross profit

(5.8 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

1.2 m2.5 m4.2 m6.8 m9.3 m6.3 m11.8 m15.1 m

Cost of goods sold

76 k304 k3.1 m1.1 m5.1 m18.2 m4.3 m4.4 m

Gross profit

1.1 m2.2 m1.1 m5.8 m4.2 m(11.9 m)7.5 m10.8 m

Gross profit Margin, %

94%88%27%84%45%(187%)64%71%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

55.7 m74.3 m200.3 m111.8 m

Accounts Receivable

834 k3.7 m5.2 m

Inventories

7.8 m41.9 m12.7 m

Current Assets

56.9 m98.6 m249.3 m132.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

67.7 m105.3 m92 m84.1 m168.8 m131.3 m102.2 m170.5 m155.8 m132.2 m90.9 m140.5 m

Accounts Receivable

156 k195 k136 k151 k1.3 m1.4 m2.6 m4.3 m5.1 m6.2 m8.5 m

Inventories

918 k27.2 m34 m36.7 m42.2 m39.7 m24.3 m12.6 m18.1 m

Current Assets

71.6 m156.4 m138.3 m122 m200.7 m171.4 m147.7 m220.2 m202.7 m160 m119.3 m175.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.7 m)(111.5 m)(123.1 m)(161.1 m)

Depreciation and Amortization

54 k306 k596 k1 m

Accounts Receivable

(834 k)(2.8 m)(1.6 m)

Inventories

(7.8 m)(29.2 m)(2.3 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(29.1 m)(13.5 m)(35.9 m)(71.2 m)(27.7 m)(54.6 m)(85.4 m)(41 m)(44.7 m)(41.7 m)(23 m)

Depreciation and Amortization

34 k32 k88 k185 k138 k283 k431 k261 k

Accounts Receivable

48 k48 k48 k(669 k)5.1 m6.2 m

Inventories

371 k39.7 m24.3 m12.6 m
USDY, 2017

Revenue/Employee

78.5 k

Financial Leverage

7.2 x
Show all financial metrics

Keryx Biopharmaceuticals Market Value History

Keryx Biopharmaceuticals's Web-traffic and Trends

Keryx Biopharmaceuticals Online and Social Media Presence

Keryx Biopharmaceuticals Company Life and Culture

You may also be interested in